A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

ID Number 13-1603

Principal Investigator(s)
Amir S Steinberg

Department(s) or Division(s)
Hematology and Medical Oncology


The main purpose of this study is to measure how the experimental study drug regimen works
compared to the non-experimental study drug regimen for Hodgkin lymphoma. Adcetris targets
CD30, a protein marker that is found on some types of cancer cells such as Hodgkin lymphoma.
This research will look to see if Adcetris may cause the cancer cells to die.

Another purpose of this study is to see how differences in DNA and RNA (genetic material) and proteins related to HL may influence the way people respond to Adcetris. This information may
be used for research related to analysis and development of Adcetris in associated disease states,
for example:
1: to understand how genes affect the safety and effectiveness of Adcetris
2: to help develop new ways to monitor and treat cancer
3: to generate information needed for research, development and regulatory approval of
  diagnostic tests related to diseases or conditions that Adcetris might treat

Contact Information
(212) 824-7309

Recruiting Patients: Yes